MXPA02009043A - Composiciones que comprenden bloqueadores de la transferencia de la celula l-dopa renal para el tratamiento de la enfermedad de parkinson. - Google Patents

Composiciones que comprenden bloqueadores de la transferencia de la celula l-dopa renal para el tratamiento de la enfermedad de parkinson.

Info

Publication number
MXPA02009043A
MXPA02009043A MXPA02009043A MXPA02009043A MXPA02009043A MX PA02009043 A MXPA02009043 A MX PA02009043A MX PA02009043 A MXPA02009043 A MX PA02009043A MX PA02009043 A MXPA02009043 A MX PA02009043A MX PA02009043 A MXPA02009043 A MX PA02009043A
Authority
MX
Mexico
Prior art keywords
dopa
renal cell
parkinson
treatment
disease
Prior art date
Application number
MXPA02009043A
Other languages
English (en)
Inventor
Da Silva Patricio Soares
Original Assignee
Portela & Ca Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Portela & Ca Sa filed Critical Portela & Ca Sa
Publication of MXPA02009043A publication Critical patent/MXPA02009043A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una composicion farmaceutica para el tratamiento de la enfermedad de Parkinson que comprende L-DOPA y por lo menos un compuesto con la capacidad para bloquear la trayectoria de transferencia hacia fuera de la celula L-DOPA renal; siendo elegido dicho compuesto bloqueador entre (a) un derivado flavonoide de fenil benzopirano; (b) un derivado trans-estilbeno; o (c) floretino [3-(4-hidroxifenil)-1-(2,4,6-trihidroxifeniI)-1-propanona]. La composicion puede comprender tambien un inhibidor de la descarboxilasa de la enzima del aminoacido (AADC), tal como carbidopa o benserazida, y/o un inhibidor de la catecol-O-metil tranferasa (COMT), tal como entacapona o tolcapona. La composicion es administrada de preferencia en forma solida y la L-DOPA puede ser administrada simultaneamente o en secuencia con el compuesto bloqueador de la transferencia hacia fuera de la celula L-DOPA renal.
MXPA02009043A 2000-03-14 2001-03-13 Composiciones que comprenden bloqueadores de la transferencia de la celula l-dopa renal para el tratamiento de la enfermedad de parkinson. MXPA02009043A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0006063A GB2348371B (en) 2000-03-14 2000-03-14 Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease
PCT/EP2001/002896 WO2001068065A2 (en) 2000-03-14 2001-03-13 Compositions comprising blockers of l-dopa renal cell transfer for the treatment of parkinson's disease

Publications (1)

Publication Number Publication Date
MXPA02009043A true MXPA02009043A (es) 2004-08-19

Family

ID=9887552

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA02009043A MXPA02009043A (es) 2000-03-14 2001-03-13 Composiciones que comprenden bloqueadores de la transferencia de la celula l-dopa renal para el tratamiento de la enfermedad de parkinson.

Country Status (23)

Country Link
US (1) US20040242503A1 (es)
EP (1) EP1267853B1 (es)
JP (1) JP3677002B2 (es)
KR (1) KR100738746B1 (es)
CN (1) CN1262269C (es)
AR (1) AR035567A1 (es)
AT (1) ATE275397T1 (es)
AU (1) AU781280B2 (es)
BR (1) BR0109220A (es)
CA (1) CA2402712C (es)
CZ (1) CZ297123B6 (es)
DE (1) DE60105401T2 (es)
DK (1) DK1267853T3 (es)
ES (1) ES2228858T3 (es)
GB (1) GB2348371B (es)
HU (1) HUP0300130A3 (es)
MX (1) MXPA02009043A (es)
PL (1) PL359327A1 (es)
PT (1) PT1267853E (es)
RU (1) RU2266111C2 (es)
SI (1) SI1267853T1 (es)
TR (1) TR200402661T4 (es)
WO (1) WO2001068065A2 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2348371B (en) * 2000-03-14 2001-04-04 Soares Da Silva Patricio Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease
US7381772B2 (en) * 2003-12-12 2008-06-03 E. I. Du Pont De Nemours And Company Toughened poly(lactic acid) compositions
WO2005121069A1 (en) 2004-06-04 2005-12-22 Xenoport, Inc. Levodopa prodrugs, and compositions and uses thereof
US8008540B2 (en) 2004-07-07 2011-08-30 Kampavata Ab Transgenic non-human animal for use in research models for studying Parkinson's disease
RU2431634C2 (ru) * 2005-03-11 2011-10-20 Говард Флори Инститьют Оф Експериментл Физиолоджи Энд Медсин Соединения флавоноидов и их применение
GB0505756D0 (en) * 2005-03-21 2005-04-27 Mars Uk Ltd Method
US20090012170A1 (en) * 2005-09-21 2009-01-08 Helena Nissinen Treatment of symptoms of motor dysfunction
US20070248590A1 (en) * 2005-12-02 2007-10-25 Sirtris Pharmaceuticals, Inc. Modulators of CDC2-like kinases (CLKS) and methods of use thereof
CN101365439B (zh) 2005-12-05 2012-12-26 克塞诺波特公司 左旋多巴前体药物甲磺酸盐、其组合物及其用途
CA2673336A1 (en) 2006-12-21 2008-06-26 Xenoport, Inc. Levodopa dimethyl-substituted diester prodrugs, compositions, and methods of use
US7829592B2 (en) 2006-12-21 2010-11-09 Xenoport, Inc. Catechol protected levodopa diester prodrugs, compositions, and methods of use
CN101951768A (zh) * 2007-02-14 2011-01-19 玛尔斯有限公司 神经原性化合物
BRPI0801239A2 (pt) * 2008-04-01 2009-11-17 Ache Lab Farmaceuticos Sa uso de um ou mais benzopiranonas, composição farmacêutica e método de prevenção ou tratamento de doenças, disfunções e distúrbios associados a monoamino oxidase
JP2012505885A (ja) 2008-10-20 2012-03-08 ゼノポート，インコーポレーテッド レボドパエステルプロドラッグを合成する方法
US8399513B2 (en) 2008-10-20 2013-03-19 Xenoport, Inc. Levodopa prodrug mesylate hydrate
US20100158829A1 (en) * 2008-12-24 2010-06-24 Conopco, Inc., D/B/A Unilever Method and Composition for Color Modulation
CN101856350A (zh) * 2009-04-13 2010-10-13 中国医学科学院药物研究所 黄芩素在制备预防和治疗帕金森病药物中的应用
NZ601747A (en) 2009-11-09 2014-08-29 Xenoport Inc Pharmaceutical compositions and oral dosage forms of a levodopa prodrug and methods of use
CN101797243B (zh) * 2010-03-23 2012-01-18 广东药学院 一种含有左旋多巴和冰片的组合物及其应用
KR101327936B1 (ko) * 2011-07-06 2013-11-13 한국식품연구원 옥시레스베라트롤 이민 유도체를 유효성분으로 함유하는 뇌신경보호 효과를 가지는 조성물
CN102755312A (zh) * 2012-07-16 2012-10-31 中国科学院大连化学物理研究所 具有黄酮骨架结构的化合物作为帕金森症治疗药物的应用
GB201302755D0 (en) 2013-02-15 2013-04-03 Mars Inc Horse supplement
CN103211832A (zh) * 2013-04-24 2013-07-24 无锡艾德美特生物科技有限公司 含杨酶苷或/和杨梅素的药物组合物及其在制备帕金森治疗药物中的用途
CN104116730A (zh) * 2013-04-26 2014-10-29 中国科学院大连化学物理研究所 二氢杨梅素作为活性成份在制备帕金森症治疗药物中的应用
KR101583399B1 (ko) * 2013-10-22 2016-01-08 충북대학교 산학협력단 아사리닌 또는 (-)-세사민을 함유하는 파킨슨병 예방 또는 치료용 약학조성물
EP3275433A1 (en) * 2016-07-29 2018-01-31 Som Innovation Biotech S.L. Sustained release composition comprising micronized tolcapone
KR102681552B1 (ko) * 2016-09-27 2024-07-04 (주)아모레퍼시픽 소장 상피세포에서의 카테킨 흡수 증진제
CN111329853A (zh) * 2020-04-21 2020-06-26 遵义医科大学 一种治疗帕金森病的药物组合物及其应用和治疗帕金森病的药物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4190672A (en) * 1978-09-01 1980-02-26 Stanley Fahn Method and compositions of treating Parkinsonisms with levodopa and 3',4'-dihydroxy-2-methylisopropiophenone
JPS5852219A (ja) * 1981-09-22 1983-03-28 Sumitomo Chem Co Ltd パ−キンソン病治療剤
JPS6450877A (en) * 1987-08-20 1989-02-27 Ichimaru Pharcos Inc Oxygen radical catching and removing agent
JPH035423A (ja) * 1989-06-01 1991-01-11 Ichimaru Pharcos Co Ltd フラボノイド含有過酸化脂質生成抑制剤
US5702752A (en) * 1996-03-13 1997-12-30 Archer Daniels Midland Company Production of isoflavone enriched fractions from soy protein extracts
JPH09241637A (ja) * 1996-03-14 1997-09-16 Chugai Pharmaceut Co Ltd 活性酸素ラジカル除去用組成物およびその方法
GB9702310D0 (en) * 1997-02-05 1997-03-26 Univ Hertfordshire Invention
JP2001521002A (ja) * 1997-10-24 2001-11-06 コーネル リサーチ ファンデーション インク． 脳の代謝機能不全のための栄養補充剤
JPH11323326A (ja) * 1998-02-06 1999-11-26 Nagaoka Koryo Kk 活性酸素消去剤、皮膚保全剤および変色防止剤
FR2787319B1 (fr) * 1998-12-22 2002-06-14 Oreal Utilisation d'hydroxystilbenes pour la teinture, composition prete a l'emploi les contenant et procede de teinture
US20010047032A1 (en) * 1999-12-30 2001-11-29 Castillo Gerardo M. Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases
GB2348371B (en) * 2000-03-14 2001-04-04 Soares Da Silva Patricio Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease
CA2813048A1 (en) * 2002-01-28 2003-08-07 Kyowa Hakko Kirin Co., Ltd. Composition for use in treating patients suffering from movement disorder

Also Published As

Publication number Publication date
ES2228858T3 (es) 2005-04-16
SI1267853T1 (en) 2005-04-30
HUP0300130A3 (en) 2005-11-28
RU2266111C2 (ru) 2005-12-20
WO2001068065A3 (en) 2002-02-21
GB0006063D0 (en) 2000-05-03
JP2003526658A (ja) 2003-09-09
DE60105401D1 (de) 2004-10-14
KR100738746B1 (ko) 2007-07-12
EP1267853B1 (en) 2004-09-08
GB2348371B (en) 2001-04-04
DK1267853T3 (da) 2005-01-10
KR20030095184A (ko) 2003-12-18
AU5828301A (en) 2001-09-24
PL359327A1 (en) 2004-08-23
TR200402661T4 (tr) 2004-11-22
HUP0300130A2 (en) 2003-05-28
CA2402712A1 (en) 2001-09-20
CA2402712C (en) 2005-05-17
CN1429109A (zh) 2003-07-09
AU781280B2 (en) 2005-05-12
JP3677002B2 (ja) 2005-07-27
EP1267853A2 (en) 2003-01-02
BR0109220A (pt) 2003-03-18
CZ20023348A3 (cs) 2003-02-12
DE60105401T2 (de) 2005-10-13
WO2001068065A9 (en) 2002-07-18
CZ297123B6 (cs) 2006-09-13
CN1262269C (zh) 2006-07-05
AR035567A1 (es) 2004-06-16
PT1267853E (pt) 2004-12-31
US20040242503A1 (en) 2004-12-02
WO2001068065A2 (en) 2001-09-20
GB2348371A (en) 2000-10-04
ATE275397T1 (de) 2004-09-15

Similar Documents

Publication Publication Date Title
MXPA02009043A (es) Composiciones que comprenden bloqueadores de la transferencia de la celula l-dopa renal para el tratamiento de la enfermedad de parkinson.
DK0841904T3 (da) Orale farmaceutiske præparater med forsinket frigivelse af reversible protonpumpeinhibitorer
WO2005041924A3 (en) Administration of levodopa and carbidopa
TW200505423A (en) Combination, kit and pharmaceutical composition for treatment of parkinson's disease
BR0210971A (pt) Formas inovadoras de dosagem de benzimidazol substituìdo e método para usar as mesmas
UY25242A1 (es) Inhibidores de benzotiazol de la proteína tirosina cinasa
WO2002058698A3 (en) Malonyl-coa decarboxylase inhibitors useful as metabolic modulators
PT942751E (pt) Composicoes para o tratamento de neuropatias perifericas contendo antiodepressivos e/ou inibidores da monoamino-oxidase e/ou vitamina b12 e/ou precursores ou indutores de neurotransmissores
WO2003045334A3 (en) Methods and compositions for ameliorating the undesirable effects of chemotherapy
HK1086548A1 (en) Deuterated catecholamine derivatives and medicaments comprising said compounds
PT965351E (pt) Composicao para alimentos dieteticos e metodo dietetico utilizando este tipo de composicao
DK1196174T3 (da) Diætmæssigt calcium, som et tilskud til D-vitamin-forbindelsesbehandling af multipel sclerose
PT1441708E (pt) Composições e métodos para aumentar a observância de terapias utilizando inibidores da aldeído desidrogenase e para tratar alcoolismo
BR0313177A (pt) Administração oral de calcitonina
DK0656178T3 (da) Nærende sammensætninger til kontrol af nitrogenmetabolismen
IT1317042B1 (it) Fumarati doppi di una carnitina e creatina, e integratori alimentari,dietetici e farmaci che li contengono.
EP1550443A4 (en) COMPOSITION AGAINST STRESS-BASED DISEASES
MXPA03005384A (es) Composiciones framaceuticas de un inhibidor de bomba de proton revestido no enterico con una combinacion de sal de bicarbonato y sal de carbonato.
PT1007034E (pt) Combinacoes que contem bergamotina para aumentar a biodisponibilidade oral de agentes farmaceuticos
WO2000053149A3 (en) Method and composition for administering a cyclooxygenase-2 inhibitor
BR0207446A (pt) Composição medicinal que contém diclofenaco e ornoprostil.
CHABANON et al. Increased translation efficiency and antizyme-dependent stabilization of ornithine decarboxylase in amino acid-supplemented human colon adenocarcinoma cells, Caco-2
EP0974351A3 (en) Medicament for preventing and treating gastrointestinal damage
ATE301469T1 (de) Pharmazeutische diclofenac-verbindung basierend auf vitamin e, papain und hyaluronidase
WO2002068389A3 (de) Indolderivate mit inhibitorischer wirkung auf phenoloxidasen

Legal Events

Date Code Title Description
FG Grant or registration